Panbela Therapeutics, Inc. (PBLA)
OTCMKTS: PBLA · Delayed Price · USD
0.340
0.00 (0.06%)
Jul 19, 2024, 3:36 PM EDT - Market open
Panbela Therapeutics Stock Forecast
PBLA's stock price has decreased by -99.22% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for PBLA stock has a target of 25, which predicts an increase of 7,248.62% from the current stock price of 0.34.
Analyst Consensus: Buy
* Price targets were last updated on Mar 27, 2024.
Analyst Ratings
The average analyst rating for PBLA stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 2 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jun 24, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 16, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $16 → $5 | Strong Buy | Maintains | $16 → $5 | +1,369.72% | Apr 2, 2024 |
| Roth MKM | Roth MKM | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +7,248.62% | Mar 27, 2024 |
| Roth MKM | Roth MKM | Strong Buy Maintains $500 → $25 | Strong Buy | Maintains | $500 → $25 | +7,248.62% | Feb 5, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-7.01
from -232.43K
EPS Next Year
-4.80
from -7.01
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | 22.4M | 92.9M | 288.9M |
| Avg | n/a | n/a | 15.2M | 62.9M | 183.1M |
| Low | n/a | n/a | 8.2M | 34.2M | 82.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 512.7% | 359.3% |
| Avg | - | - | - | 315.0% | 191.1% |
| Low | - | - | - | 125.7% | 30.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -5.63 | -3.94 | -2.92 | 0.22 | 13.76 |
| Avg | -7.01 | -4.80 | -4.50 | -0.41 | 6.91 |
| Low | -8.21 | -5.55 | -5.92 | -0.99 | 0.43 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.